HENGRUI PHARMA (01276) has released its results for the first three quarters of 2026, reporting revenue of approximately RMB 24.409 billion, an increase of 5.26% year-on-year.
Net profit attributable to shareholders of the listed company came in at approximately RMB 6.923 billion, up 20.38% year-on-year, while net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 6.243 billion, up 11.70% year-on-year. Basic earnings per share stood at RMB 1.05.
The company continued to strengthen its innovation efforts and maintained a high level of research and development investment. In the first three quarters of 2026, cumulative R&D spending reached RMB 7.146 billion, of which RMB 5.423 billion was expensed.
During the first three quarters of 2026, sales revenue from innovative drugs reached RMB 13.871 billion, up 17.05% year-on-year, raising its share of pharmaceutical sales revenue to 64.59%.
Within innovative drug sales revenue, revenue from anti-tumor innovative products was RMB 9.865 billion, up 3.13% year-on-year, accounting for 71.12% of total innovative drug sales revenue. Revenue from non-tumor innovative products was RMB 4.006 billion, up 75.36% year-on-year, accounting for 28.88% of total innovative drug sales revenue.
In the first three quarters of 2026, the company recognized revenue of RMB 2.781 billion from outbound licensing of innovative drugs, up 31.12% year-on-year, mainly comprising revenue recognized from GSK and BMS based on the progress of fulfillment of performance obligations, as well as milestone payments from certain licensed products.
The company received a total of RMB 4.343 billion in cash from upfront payments and milestone payments under outbound licensing collaborations, mainly the US$600 million upfront payment from BMS.
Comments